CoRe­gen clos­es $93M fi­nanc­ing round to en­ter the clin­ic and ex­pand its lead­er­ship team

Clin­i­cal-stage gene ther­a­py biotech CoRe­gen has se­cured $93.4 mil­lion in a fi­nanc­ing round to de­vel­op its man­u­fac­tur­ing process­es, fund its first clin­i­cal study and build …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER